收藏切换
Trends of new drug R&D and approval in China: an analysis of the data of new drug applications from 2016 to 2020 by NMPA
收藏切换
PDF
Wen-wen WANG, Man-li HUANG, Chui-xiong CHEN, Chen LI, Ling WANG
Chinese Journal of New Drugs | 2023, 32(4) : 386 - 395
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(4): 386-395
Trends of new drug R&D and approval in China: an analysis of the data of new drug applications from 2016 to 2020 by NMPA
Full
Wen-wen WANG, Man-li HUANG, Chui-xiong CHEN, Chen LI, Ling WANG
Affiliations
  • Department of Health Statistics, Department of Military Prevention, Air Force Military Medical University, Xi'an 714600, China
Published: 2023-02-28
Outline
收藏切换

The situation of new drug approval by the State Drug Administration (NMPA) from 2016 to 2020 was systematically analyzed and compared with that by the Food and Drug Admin-istration (FDA) of the United States in the same period, the trend of drug R&D in China in the past five years was analyzed, and the trend of new drug R&D and approval in China from 2016 to 2020 were summarized. Combined with China's drug administrative supervision and management regulations, the status and role of China in global drug R&D were analyzed. It was found that a total of 956 new drug applications (NDA) were approved by NMPA from 2016 to 2020, including 471 for chemicals, 235 for traditional Chinese medicine, and 250 for biopharmaceuticals. The number of new drugs approved by NMPA continued to increase in the 5 years. Compared with the application and approval of FDA, the number of drugs de-clared in China was larger, but the proportion of approval was smaller, the number of first-class innovative drugs was smaller, the main indications for approved listed drugs were anti-tumor, digestive system and anti-infection, and the R&D of drugs for rare diseases and orphans were insufficient. The number of approved new drugs in China was increasing year by year, but the proportion of local original research and new drugs was relatively small, basic research and transformation research was weak, and the R&D of new target molecular drugs was not enough.

drug discovery  /  approval of new drugs  /  new drug application
Wen-wen WANG, Man-li HUANG, Chui-xiong CHEN, Chen LI, Ling WANG. Trends of new drug R&D and approval in China: an analysis of the data of new drug applications from 2016 to 2020 by NMPA[J]. Chinese Journal of New Drugs, 2023 , 32 (4) : 386 -395 .
Year 2023 volume 32 Issue 4
PDF
38
13
Cite this Article
BibTeX
Article Info
  • Online Date:2026-03-05
  • Published:2023-02-28
Article Data
Affiliations
History
  • Accepted:2022-09-19
Funding
Affiliations
    Department of Health Statistics, Department of Military Prevention, Air Force Military Medical University, Xi'an 714600, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT